Albumin infusion (albumin)

Phase 2

Grifols SA (GRFS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

GRFSPhase 2$5.0B

Albumin infusion (albumin) Phase 2 Est. Readout

Albumin infusion (albumin)• Cirrhosis20

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Cirrhosis

View Full Landscape

Drug Information

Target Indication

Cirrhosis

Clinical Trial

NCT06812390

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GRFS

Grifols SA

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

alpha-1 proteinase inhibitor (human)Phase 3

Alpha 1-Antitrypsin Deficiency

FS GrifolsPhase 3

Target Bleeding Site During Peripheral Vascular Surgery

Liquid Alpha₁-PIPhase 3

Alpha₁-Antitrypsin Deficiency

Alpha-1 MPPhase 3

Alpha 1-Antitrypsin Deficiency

Fibrin Sealant (FS) GrifolsPhase 3

Soft Tissue Surgical Bleeding

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts